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TABLE 2
Biodistribution of Technetium-99m-PEG Liposomes (120 nm) with 
Increasing PS Content in Rats with S. aureus Infection in Left Calf
Muscle 24 Hours Postinjection (%ID/g ± s.d.)
10 mole%
0% PS 1 mole% PS PS
Blood 0.84 ± 0.05 0.09 ± 0.01 0.03 ± 0.01
Muscle 0.04 ± 0.01 0.01 ± 0.002 0.01 ± 0.01
Bone marrow 0.92 ± 0.23 0.93 ± 0.26 1.26 + 0.72
Bone 0.16 + 0.05 0.10 ± 0.04 0.57 + 0.87
Abscess 1.10 ±0.14 0.34 ± 0.21 0.16 ±0.05
Lung 0.28 ± 0.03 0.08 ± 0.01 0.04 ± 0.01
Spleen 7.95 ± 1.14 17.8 ±4.1 20.4 ± 4.4
Kidney 3.36 ± 0.32 4.33 ± 0.49 4.17 + 0.57
Liver 0.81+0.12 1.04 ±0.22 1.31+0.21














t ime postinjection (hr)
in the abscess, PS incorporation induced an enhanced deposition of 
PEG liposomes in tissues rich in mononuclear phagocytes, partic­
ularly enhanced uptake in the spleen was observed.
Quantification of the scintigraphic images clearly shows the 
drastic effect of PS incorporation in the lipid bilayer on the 
circulation kinetics of the PEG liposomes (Fig. 4). The i/2PS- 
containing PEG liposomes were cleared much faster (initial t>h ^  
3 hr) than the non-PS-containing PEG liposomes. Whole-body 
clearance of the PS-containing liposomal preparations was slightly 
enhanced as compared to that of the non-PS-containing preparation 
(whole-body retention at 24 hr postinjection: 59% ± 2% versus 
50% ± 3%, respectively).
The effect of PS incorporation on the abscess-to-background 
ratios is shown in Figure 5. The highest abscess-to-background 
ratios were obtained with the PEG liposomes without PS and with 
1.0 mole% PS (6.7 ± 0.4 and 6.6 ± 1.7, respectively). These ratios 
were significantly higher than those obtained with the 10 mole% 
PS-containing PEG liposomes from 6 hr onwards (p <  0.05).
DISCUSSION
In previous preclinical studies, we have shown that PEG 
liposomes labeled with H1In or " mTc preferentially localize in 
infectious and inflammatory foci (1,2). The mechanism of 
abscess uptake of PEG liposomes remains to be elucidated. 
Studies have shown that uptake of PEG liposomes by mono­
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FIGURE 4. Quantitative analysis of the scintigraphic images of rats (three rats 
per group) injected with 99rf1Tc-labeled PEG liposomes with different PS 
content. Blood-pool activity measured 5 min postinjection was set at 100%. 
Error bars represent s.d.
FIGURE 5. Quantitative analysis of the scintigraphic images of rats (three rats 
per group) injected with 99mTc-labeied PEG liposomes with different PS 
content. The region in the uninfected contralateral right calf muscle was 
taken as the background region. Error bars represent s.d.
extravasate in areas of inflammation as a result of locally 
enhanced capillary permeability.
In our previous experiments, we used a PEG liposome 
fonnulation developed for delivery of chemotherapeutics to 
tumors and infectious foci (10,27). In these liposomal drug 
targeting applications, one aims to maximize the localization of 
the drug at the pathological site. When using radiolabeled PEG 
liposomes to image infectious or inflammatory foci, one aims to 
achieve an optimal compromise between sufficient target up­
take and maximal target-to-background ratios relatively early 
after injection. In this study, we investigated whether the PEG 
liposome formulation can be optimized for the latter purpose.
Carefully tuning the size of the PEG liposomes had a marked 
effect on their in vivo distribution after intravenous administra­
tion. Blood clearance of the larger PEG liposomes was faster 
than that of smaller liposomes (Fig. 3), which has also been 
observed for non-PEGylated liposomes (28). In addition, the 
splenic uptake of these liposomes was markedly higher than 
that of the smaller PEG liposomes (Table 1). PEG liposomes 
with a mean diameter of 90 nm combined two favorable charac­
teristics for imaging: optimal uptake in the infectious focus and 
relatively low splenic uptake (Fig. 1). The abscess was visualized 
as early as 1 hr postinjection, and target-to-background ratios 
improved with time (Fig. 2). In the rat model used in this study, the 
abscess uptake of these 90-nm PEG liposomes was higher than the 
abscess uptake obtained with the PEG-liposomal preparation we 
used in our previous studies (1.6%ID/g versus l.Q%ID/g) (2). In 
addition, the splenic uptake of the 90-nm PEG liposomes was 
considerably lower (6.9%ID/g versus 12.5%ID/g). The liposomal 
formulation used in our previous studies was prepared using a 
microfluidizer, yielding a preparation with a similar mean size, but 
with a much wider size distribution (polydispersity index: 0.4 
versus 0.2). Most likely, the earlier formulation contained a 
relatively higher proportion of larger liposomes with consequently 
reduced abscess uptake and increased splenic uptake. As compared 
to the 111 In-labeled PEG liposomes used in our previous study (1) 
the 90-nm " mTc-labeled PEG liposomes described here displayed 
a somewhat reduced abscess uptake (1.9%ID/g versus 1.6%ID/g). 
However, abscess-to-muscle ratios obtained with the 90-nm PEG 
liposomes were higher (20 versus 35).
The biodistribution as well as imaging data indicate that the
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larger the liposomes the higher their splenic uptake. The 
remarkably high and rapid splenic uptake of the 220-nm 
liposomes is most likely due to physical filtration rather than 
phagocytosis by spleen macrophages (19,29). Using flúores- 
cence microscopy, it has been shown that larger PEG liposomes 
localize in the red pulp and marginal zone without being 
internalized by macrophages (50).
Imaging cannot only be improved by enhancing uptake in the 
target, but also by reducing background activity. We studied the 
effect of enhanced blood (and thus background) clearance by 
using PS inclusion as a tool to modulate circulation time. PS is 
asymmetrically distributed in mammalian cell membranes, 
being preferentially localized in the inner leaflet. Studies have 
shown that PS exposure in the outer leaflet of the cell mem­
brane serves as a signal for triggering their recognition by 
macrophages (31). Presumably, PS-containing liposomes are 
cleared from the blood by the same mechanism. The reduced 
circulatory half-life of the PS-containing PEG liposomes (Fig. 
4 ), however, caused a substantial reduction of the absolute 
abscess uptake as compared to PEG liposomes without PS. Still, 
abscess-to-blood ratios were at least three times higher for the 
PEG liposomes with 1 mole% PS incorporated in the lipid 
bilayers. The enhanced accumulation of the PS-containing 
liposomes in liver and spleen confirmed that their enhanced 
clearance from the blood was most likely mediated by cells of 
the mononuclear phagocytotic system. This enhanced splenic 
and hepatic uptake indicates that the radiolabel was retained in 
the cells rather than excreted after phagocytosis of the PS- 
containing PEG liposomes by MPS cells. Consequently, while 
abscess-to-blood ratios improved on incorporation of PS, ab- 
scess-to-background ratios for liver and spleen decreased. 
Enhanced blood clearance will lead to improved abscess-to- 
background ratios only when the radiolabel is excreted from the 
body after uptake of the liposomes by MPS cells. In principle, 
this might be achieved by using chelated radionuclides that can 
be excreted after being released from the liposomes.
The circulatory half-life of liposomes can also be enhanced 
without the use of PEG, by preparing small liposomes com­
posed of bilayers with a rigid nature (14,15). We have chosen to 
use sterically stabilized liposomes, as such liposomes allow 
fine-tuning for a particular application, while the formulation of 
the small and rigid liposomes mostly cannot be modified 
without compromising their long circulating characteristic. An 
additional advantage of the use of PEG liposomes is that the 
circulation time of PEG liposomes is relatively independent of 
the lipid dose administered (18).
CONCLUSION
PEG liposomes can be fine-tuned to allow optimal imaging of 
focal infection. PEG liposomes with a mean size of 90 nm showed 
superior imaging characteristics as compared to larger-sized PEG 
liposomes. Enhanced blood clearance improved the preparation 
only partially, mainly because the radiolabel was not excreted from 
the body after being eliminated from the circulation.
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